147 related articles for article (PubMed ID: 15585048)
1. The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus.
Kumaranayake L; Vickerman P; Walker D; Samoshkin S; Romantzov V; Emelyanova Z; Zviagin V; Watts C
Addiction; 2004 Dec; 99(12):1565-76. PubMed ID: 15585048
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine.
Vickerman P; Kumaranayake L; Balakireva O; Guinness L; Artyukh O; Semikop T; Yaremenko O; Watts C
Sex Transm Dis; 2006 Oct; 33(10 Suppl):S89-102. PubMed ID: 16735956
[TBL] [Abstract][Full Text] [Related]
3. Could the CARE-SHAKTI intervention for injecting drug users be maintaining the low HIV prevalence in Dhaka, Bangladesh?
Foss AM; Watts CH; Vickerman P; Azim T; Guinness L; Ahmed M; Rodericks A; Jana S
Addiction; 2007 Jan; 102(1):114-25. PubMed ID: 17207129
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
[TBL] [Abstract][Full Text] [Related]
5. Country-wide distribution of the nitrile female condom (FC2) in Brazil and South Africa: a cost-effectiveness analysis.
Dowdy DW; Sweat MD; Holtgrave DR
AIDS; 2006 Oct; 20(16):2091-8. PubMed ID: 17053355
[TBL] [Abstract][Full Text] [Related]
6. Coverage to curb the emerging HIV epidemic among injecting drug users in Pakistan: delivering prevention services where most needed.
Emmanuel F; Fatima M
Int J Drug Policy; 2008 Apr; 19 Suppl 1():S59-64. PubMed ID: 18281206
[TBL] [Abstract][Full Text] [Related]
7. Estimating the cost-effectiveness of needle-syringe programs in Australia.
Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.
Pinkerton SD; Martin JN; Roland ME; Katz MH; Coates TJ; Kahn JO
Arch Intern Med; 2004 Jan; 164(1):46-54. PubMed ID: 14718321
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of a behavioral intervention for seropositive youth.
Lee MB; Leibowitz A; Rotheram-Borus MJ
AIDS Educ Prev; 2005 Apr; 17(2):105-18. PubMed ID: 15899749
[TBL] [Abstract][Full Text] [Related]
10. The epidemiological impact and cost-effectiveness of HIV testing, antiretroviral treatment and harm reduction programs.
Li J; Gilmour S; Zhang H; Koyanagi A; Shibuya K
AIDS; 2012 Oct; 26(16):2069-78. PubMed ID: 22781221
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of methadone maintenance therapy as HIV prevention in an Indonesian high-prevalence setting: a mathematical modeling study.
Wammes JJ; Siregar AY; Hidayat T; Raya RP; van Crevel R; van der Ven AJ; Baltussen R
Int J Drug Policy; 2012 Sep; 23(5):358-64. PubMed ID: 22884538
[TBL] [Abstract][Full Text] [Related]
12. The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda.
Gray RH; Li X; Kigozi G; Serwadda D; Nalugoda F; Watya S; Reynolds SJ; Wawer M
AIDS; 2007 Apr; 21(7):845-50. PubMed ID: 17415039
[TBL] [Abstract][Full Text] [Related]
13. Needle exchange programs: an economic evaluation of a local experience.
Gold M; Gafni A; Nelligan P; Millson P
CMAJ; 1997 Aug; 157(3):255-62. PubMed ID: 9269195
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh.
Guinness L; Vickerman P; Quayyum Z; Foss A; Watts C; Rodericks A; Azim T; Jana S; Kumaranayake L
Addiction; 2010 Feb; 105(2):319-28. PubMed ID: 19922513
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of harm reduction in preventing HIV among injecting drug users.
Wodak A; Maher L
N S W Public Health Bull; 2010; 21(3-4):69-73. PubMed ID: 20513304
[TBL] [Abstract][Full Text] [Related]
16. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
[TBL] [Abstract][Full Text] [Related]
17. Efficient allocation of resources to prevent HIV infection among injection drug users: the Prevention Point Philadelphia (PPP) needle exchange program.
Harris ZK
Health Econ; 2006 Feb; 15(2):147-58. PubMed ID: 16145716
[TBL] [Abstract][Full Text] [Related]
18. Qualitative evaluation of a peer-based needle syringe programme in Vietnam.
Ngo AD; Schmich L; Higgs P; Fischer A
Int J Drug Policy; 2009 Mar; 20(2):179-82. PubMed ID: 18242971
[TBL] [Abstract][Full Text] [Related]
19. Global HIV cohort studies among injecting drug users and future vaccine trials.
Woratanarat T
J Med Assoc Thai; 2006 Jul; 89(7):1064-79. PubMed ID: 16881444
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.
Alistar SS; Owens DK; Brandeau ML
PLoS Med; 2011 Mar; 8(3):e1000423. PubMed ID: 21390264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
